Forbes May 12, 2022
Katie Jennings

The second year of the Covid-19 pandemic continued to be a boon to the world’s largest pharmaceutical companies that have developed vaccines and therapeutics to combat the virus. With the spread of new variants, the federal government has recommended booster shots and more widespread availability of anti-Covid drugs, as society grapples with the shift towards an endemic virus that will be around for the long haul. Health insurers saw high costs from Covid patients, but these were partially offset by higher enrollment in Obamacare and Medicare Advantage plans and other patients still deferring non-urgent and elective surgeries.

Seven pharmaceutical companies and four health insurers ranked among the top 100 companies in the 2022 Forbes Global 2000, which ranks the world’s...

Today's Sponsors

H1
ZeOmega
Holon

Today's Sponsors

SalesSparx
Canton & Company

Today's Sponsor

Premier

 
Topics: Healthcare System, Insurance, Pharma / Biotech, Provider, Survey / Study, Trends
5 Highlights from BlueCare Network's Rx Precision Medicine Pilot
State Actions to Address Nursing Home Staffing During COVID-19
Government COVID-19 subsidies helped hospitals when pandemic spread in 2020
Considerations for Social Determinants of Health Screening Design
Americans can expect to pay a lot more for medical care in retirement